Neural correlates of the psychedelic state as determined by fMRI studies with psilocybine Robin L. Carhart-Harris, David Erritzoe, Tim Williams, James M. Stone, Laurence J. Reed, Alessandro Colasanti, Robin J. Tyacke, Robert Leech, Andrea L. Malizia, Kevin Murphy, Peter Hobden, John Evans, Amanda Feilding, Richard G. Wise, and David J. Nutt PNAS, Proceedings of the National Academy of Sciences of the USA, 2012, 109, (6), 2138-2143. doi:10.1073/pnas.1119598109 www.pnas.org/lookup/suppl/doi:10.1073/pnas.1119598109/-/DCSupplemental. Abstract Psychedelic drugs have a long history of use in healing ceremonies, but despite renewed interest in their therapeutic potential, we continue to know very little about howthey work in the brain. Here we used psilocybin, a classic [...]
Lire la suitePsychedelic microdosing benefits and challenges : an empirical codebook Thomas Anderson, Rotem Petranker, Adam Christopher, Daniel Rosenbaum, Cory Weissman, Le-Anh Dinh-Williams, Katrina Hui, Emma Hapke Harm Reduction Journal, 2019. Doi : 10.1186/s12954-019-0308-4 Abstract Background : Microdosing psychedelics is the practice of consuming very low, sub-hallucinogenic doses of a psychedelic substance, such as lysergic acid diethylamide (LSD) or psilocybin-containing mushrooms. According to media reports, microdosing has grown in popularity, yet the scientific literature contains minimal research on this practice. There has been limited reporting on adverse events associated with microdosing, and the experiences of microdosers in community samples have not been categorized. Methods : In the present study, [...]
Lire la suitePilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Charles S. Grob, Alicia L. Danforth, Gurpreet S. Chopra, Marycie Hagerty, Charles R. McKay, Adam L. Halberstadt, George R. Greer Archive of General Psychiatry, 2010, 68, (1), 71–78 doi: 10.1001/archgenpsychiatry.2010.116 Context : Researchers conducted extensive investigations of hallucinogens in the 1950s and 1960s. By the early 1970s, however, political and cultural pressures forced the cessation of all projects. This investigation reexamines a potentially promising clinical application of hallucinogens in the treatment of anxiety reactive to advanced-stage cancer. Objective : To explore the safety and efficacy of psilocybin in patients with advanced-stage cancer and [...]
Lire la suiteNeurometabolic Effects of Psilocybin, 3,4-Methylenedioxyethylamphetamine (MDE) and d-Meth-amphetamine in Healthy Volunteers. A Double-Blind, Placebo-Controlled PET Study with [18 F] FDG Euphrosyne Gouzoulis-Mayfrank, Mathias Schreckenberger, Osama Sabri, Christoph Arning, Bernhard Thelen, Manfred Spitzer, Ph.D., Karl-Artur Kovar, Leopold Hermle, Udalrich Büll, and Henning Sass. NEUROPSYCHOPHARMACOLOGY, 1999–VOL 20, NO 6, 565-581. PII S0893-133X(98)00089-X The neurometabolic effects of the hallucinogen psilocybin (PSI; 0.2 mg/kg), the entactogen 3,4- methylenedioxyethylamphetamine (MDE; 2 mg/kg) and the stimulant d-methamphetamine (METH; 0.2–0.4 mg/kg) and the drugs’ interactions with a prefrontal activation task were investigated in a double-blind, placebo-controlled human [F-18]fluorodeoxyglucoseFDG-positron emission tomographicPET study (each group: n 5 8). Subjects underwent two scans (control: [...]
Lire la suitePsychedelic therapy for smoking cessation : Qualitative analysis of participant accounts Tehseen Noorani, Albert Garcia-Romeu, Thomas C. Swift, Roland R. Griffiths and Matthew W. Johnson Journal of Psychopharmacology, 2018, 1 –14 https://doi.org/10.1177/0269881118780 Abstract Background : Recent pilot trials suggest feasibility and potential efficacy of psychedelic-facilitated addiction treatment interventions. Fifteen participants completed a psilocybin-facilitated smoking cessation pilot study between 2009 and 2015. Aims : The aims of this study were as follows: (1) to identify perceived mechanisms of change leading to smoking cessation in the pilot study; (2) to identify key themes in participant experiences and long-term outcomes to better understand the therapeutic process. Methods : Participants were [...]
Lire la suiteSerotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease : A systematic review Simon Reiche, Leo Hermle, Stefan Gutwinskic Henrik Jungaberle, Peter Gasser, Tomislav Majić Progress in Neuropsychopharmacology & Biological Psychiatry, 2018, 81, 1–10 http://dx.doi.org/10.1016/j.pnpbp.2017.09.012 A B S T R A C T Anxiety and depression are some of the most common psychiatric symptoms of patients suffering with lifethreatening diseases, often associated with a low quality of life and a poor overall prognosis. 5-HT2A-receptor agonists (serotonergic hallucinogens, ‘psychedelics’) like lysergic acid diethylamide (LSD) and psilocybin were first investigated as therapeutic agents in the 1960s. Recently, after a long [...]
Lire la suitePsilocybin Scientific Papers AEDMP - Asociación para el Estudio y la Divulgación de la Medicina Psicodélica Research conducted by: Fco. Miguel Ríos & Genís Oña - 2014 - Asociación para el Estudio y la Divulgación de la Medicina Psicodélica. Castellarnau, 11 2º 1ª 43004 Tarragona Spain Tel. 675 55 33 44 Email: medicina.psicodelica@hotmail.com www.medicinapsicodelica.org Content _____________________________________ 1. What is Psilocybin? 2. Scientific papers about Psilocybin arranged chronologically (1959-2014) - A. Hofmann (1959). Chemical Aspects of Psilocybin, the Psychotropic Principle from the Mexican Fungus, Psilocybe Mexicana Heim - S. Malitz et al. (1960). Some Observations on Psilocybin, a New Hallucinogen, in Volunteer Subjects - L. E. [...]
Lire la suiteLe microdosage de substances psychédéliques : bref historique et nouveaux axes de recherche Vittorio Biancardi Revue CIRCE, 2019, 11, 25pp Résumé Le micro-dosage est un phénomène social de plus en plus répandu parmi la communauté des consommateurs et consommatrices des substances dites psychédéliques. Il consiste une consommation d’un dixième de la dose typique de substance (principalement LSD ou Psilocybine) de façon fréquente, deux ou trois fois par semaine, pour améliorer les capacités cognitives ou comme auto-thérapie. L’analyse de ce phénomène est actuellement très fragmentaire et inconsistante, tant du point de vue des sciences humaines que du point de vue des sciences dites «dures». L’objectif [...]
Lire la suiteMotives and Side-Effects of Microdosing With Psychedelics Among Users Nadia R. P. W. Hutten, Natasha L. Mason, Patrick C. Dolder, Kim P. C. Kuypers International Journal of Neuropsychopharmacology, 2019, 1–9 doi:10.1093/ijnp/pyz029 Abstract Background : Microdosing with psychedelics has gained considerable media attention where it is portrayed as a performance enhancer, especially popular on the work floor. While reports are in general positive, scientific evidence about potential negative effects is lacking aside from the prevalence and motives for use. The present study addressed this gap by surveying psychedelic users about their experience with microdosing including their dosing schedule, motivation, and potential experienced negative effects. Methods : An [...]
Lire la suiteThe abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act Matthew W. Johnson, Roland R. Griffiths, Peter S. Hendricks, Jack E. Henningfiel Neuropharmacology, 2018, 142, 143-166. https://doi.org/10.1016/j.neuropharm.2018.05.012 a b s t r a c t This review assesses the abuse potential of medically-administered psilocybin, following the structure of the 8 factors of the US Controlled Substances Act (CSA). Research suggests the potential safety and efficacy of psilocybin in treating cancer-related psychiatric distress and substance use disorders, setting the occasion for this review. A more extensive assessment of abuse potential according to an 8-factor analysis would eventually be required to [...]
Lire la suite